XOMAO
$25.33-0.02 (-0.08%)
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commerc...
Recent News
XOMA Royalty Q4 Earnings Call Highlights
XOMA Royalty (NASDAQ:XOMA) executives used the company’s 2025 financial results call to emphasize a year of portfolio expansion, rising royalty receipts, and what management described as progress toward a business model in which recurring royalties can cover core operating costs. Management highlig
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses
Key Insights Given the large stake in the stock by institutions, XOMA Royalty's stock price might be vulnerable to...
XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years
XOMA Royalty Corporation ( NASDAQ:XOMA ) shareholders might understandably be very concerned that the share price has...
Huge Insider Buying in MGM and Salesforce
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug
Xoma stock plummeted Thursday after its partner, Rezolute, said its treatment for hyperinsulinism failed in Phase 3 testing.